Top

Published in:

12-12-2023 | Chronic Kidney Disease | Nephrology - Original Paper

Characterization of gut microbiota in patients with stage 3–4 chronic kidney disease: a retrospective cohort study

Authors: Xiali Yang, Shiying Cai, Jinsheng Gong, Jun Zhang, Minling Lian, Rufu Chen, Linghui Zhou, Peijin Bai, Bo Liu, Minting Zhuang, Honghong Tan, Juan Xu, Meizhen Li

Published in: International Urology and Nephrology | Issue 5/2024

Abstract

Purpose

Multiple factors, such as dietary patterns, pharmaceutical interventions, and exposure to harmful substances, possess the capacity to influence gut microbiota composition. Gut microbiota dysbiosis has emerged as a significant contributor to the progression of chronic kidney disease (CKD) and its associated complications. By comprehending the intricacies of the intestinal microbiota, this research endeavor holds the potential to offer novel perspectives on potential strategies for mitigating CKD progression.

Methods

In this retrospective analysis, we assessed gut microbiota composition in CKD patients. Fecal samples were collected from a cohort of 44 patients with stage 3–4 CKD, alongside a control group consisting of 132 healthy volunteers. Subsequently, 16 s rDNA sequencing was conducted to examine the composition of the gut microbiota.

Results

Our findings revealed significant alterations in the diversity of intestinal microbiota in fecal samples between patients with stage 3–4 CKD and healthy subjects. Among the 475 bacterial genera, 164 were shared, while 242 dominant genera were exclusive to healthy subjects and 69 to CKD stages 3–4 samples. Notably, healthy volunteers exhibited a prevalence of intestinal Firmicutes and Bacteroidetes, whereas stage 3–4 CKD patients displayed higher abundance of Proteobacteria and Actinobacteria. The presence of uncultured Coprobacillus sp. notably contributed to distinguishing between the two groups. ROC curve analysis identified distinct microbiota with superior diagnostic efficacy for discriminating stage 3–4 CKD patients from healthy individuals. Metabolic pathway analysis revealed differing dominant pathways between the two groups—the NADH dehydrogenase pathway in healthy individuals and the phosphate acetyltransferase pathway in stage 3–4 CKD patients. Moreover, the CKD cohort displayed a higher proportion of Gram-negative bacteria and facultative anaerobes.

Conclusions

In conclusion, our study underscores the profound influence of gut microbiota dysbiosis on CKD progression. The distinct microbial profiles observed in CKD patients highlight the potential efficacy of microbiota-based interventions in mitigating CKD advancement.

Available only for authorised users

Yang C, Wang H, Zhao X, Matsushita K, Coresh J, Zhang L, Zhao MH (2020) CKD in China: evolving spectrum and public health implications. Am J Kidney Dis 76:258–264. https://doi.org/10.1053/j.ajkd.2019.05.032CrossRefPubMed

Chen TK, Knicely DH, Grams ME (2019) Chronic kidney disease diagnosis and management: a review. JAMA 322:1294–1304. https://doi.org/10.1001/jama.2019.14745CrossRefPubMedPubMedCentral

Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet (London, England) 389:1238–1252. https://doi.org/10.1016/s0140-6736(16)32064-5CrossRefPubMed

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11:e0158765. https://doi.org/10.1371/journal.pone.0158765CrossRefPubMedPubMedCentral

Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ (2013) Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney int Suppl 3:1–150

Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007CrossRefPubMed

Ammirati AL (2020) Chronic kidney disease. Rev Assoc Med Bras 66(1):03–09. https://doi.org/10.1590/1806-9282.66.s1.3CrossRef

KDOQI Clinical Practice Guideline for Diabetes and CKD (2012) 2012 Update. Am J Kidney Dis 60:850–886. https://doi.org/10.1053/j.ajkd.2012.07.005CrossRef

Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D (2017) Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 179:24–37. https://doi.org/10.1016/j.trsl.2016.04.007CrossRefPubMed

10.

Cresci GA, Bawden E (2015) Gut microbiome: what we do and don’t know. Nut in Clin Prac 30:734–746. https://doi.org/10.1177/0884533615609899CrossRef

11.

Heintz-Buschart A, Wilmes P (2018) Human gut microbiome: function matters. Trends Microbiol 26:563–574. https://doi.org/10.1016/j.tim.2017.11.002CrossRefPubMed

12.

Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I (2015) Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 7:2839–2849. https://doi.org/10.3390/nu7042839CrossRefPubMedPubMedCentral

13.

Ikeda T, Nishida A, Yamano M, Kimura I (2022) Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacol Ther 239:108273. https://doi.org/10.1016/j.pharmthera.2022.108273CrossRefPubMed

14.

Schmidt TSB, Raes J, Bork P (2018) The human gut microbiome: from association to modulation. Cell 172:1198–1215. https://doi.org/10.1016/j.cell.2018.02.044CrossRefPubMed

15.

Guven G, Hilty MP, Ince C (2020) Microcirculation: physiology, pathophysiology, and clinical application. Blood Purif 49:143–150. https://doi.org/10.1159/000503775CrossRefPubMed

16.

Vasylyeva TL, Singh R (2016) Gut microbiome and kidney disease in pediatrics: does connection exist? Front Microbiol 7:235. https://doi.org/10.3389/fmicb.2016.00235CrossRefPubMedPubMedCentral

17.

Muskiet MH, Smits MM, Morsink LM, Diamant M (2014) The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 10:88–103. https://doi.org/10.1038/nrneph.2013.272CrossRefPubMed

18.

Evenepoel P, Poesen R, Meijers B (2017) The gut-kidney axis. Pediatric Nephrol (Berlin, Germany) 32:2005–2014. https://doi.org/10.1007/s00467-016-3527-xCrossRef

19.

Yang T, Richards EM, Pepine CJ, Raizada MK (2018) The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol 14:442–456. https://doi.org/10.1038/s41581-018-0018-2CrossRefPubMedPubMedCentral

20.

Shi N, Li N, Duan X, Niu H (2017) Interaction between the gut microbiome and mucosal immune system. Mil Med Res 4:14. https://doi.org/10.1186/s40779-017-0122-9CrossRefPubMedPubMedCentral

21.

Lohia S, Vlahou A, Zoidakis J (2022) Microbiome in chronic kidney disease (CKD): an omics perspective. Toxins. https://doi.org/10.3390/toxins14030176CrossRefPubMedPubMedCentral

22.

Plata C, Cruz C, Cervantes LG, Ramírez V (2019) The gut microbiota and its relationship with chronic kidney disease. Int Urol Nephrol 51:2209–2226. https://doi.org/10.1007/s11255-019-02291-2CrossRefPubMed

23.

Stedman A, Nigro G, Sansonetti PJ (2016) Microbiota-intestinal stem cells dialog: a key element for intestinal regeneration. Med Sci 32:983–990. https://doi.org/10.1051/medsci/20163211014CrossRef

24.

Fakhoury HMA, Kvietys PR, AlKattan W, Anouti FA, Elahi MA, Karras SN, Grant WB (2020) Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation. J Steroid Biochem Mol Biol 200:105663. https://doi.org/10.1016/j.jsbmb.2020.105663CrossRefPubMed

25.

Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, Zhang L, Zhang C, Bian W, Zuo L et al (2020) Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut 69:2131–2142. https://doi.org/10.1136/gutjnl-2019-319766CrossRefPubMed

26.

Liu JR, Miao H, Deng DQ, Vaziri ND, Li P, Zhao YY (2021) Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation. Cell Mol Life Sci CMLS 78:909–922. https://doi.org/10.1007/s00018-020-03645-1CrossRefPubMed

27.

Ward T, Larson J, Meulemans J, Hillmann B, Lynch J, Sidiropoulos D, Spear J, Caporaso G, Blekhman R, Knight R (2017) BugBase predicts organism level microbiome phenotypes. Genome Biol 62:1479

28.

Al Bander Z, Nitert MD, Mousa A, Naderpoor N (2020) The gut microbiota and inflammation: an overview. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph17207618CrossRefPubMedPubMedCentral

29.

Virtue AT, McCright SJ, Wright JM, Jimenez MT, Mowel WK, Kotzin JJ, Joannas L, Basavappa MG, Spencer SP, Clark ML et al (2019) The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aav1892CrossRefPubMedPubMedCentral

30.

Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, Ardalan M, Zununi Vahed S (2017) The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharm 93:412–419. https://doi.org/10.1016/j.biopha.2017.06.066CrossRef

31.

Hobby GP, Karaduta O, Dusio GF, Singh M, Zybailov BL, Arthur JM (2019) Chronic kidney disease and the gut microbiome. Am J Physiol Renal Physiol 316:F1211-f1217. https://doi.org/10.1152/ajprenal.00298.2018CrossRefPubMedPubMedCentral

32.

Chaves LD, McSkimming DI, Bryniarski MA, Honan AM, Abyad S, Thomas SA, Wells S, Buck M, Sun Y, Genco RJ et al (2018) Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis. Am J Physiol Renal Physiol 315:F487-f502. https://doi.org/10.1152/ajprenal.00092.2018CrossRefPubMedPubMedCentral

33.

Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39:230–237. https://doi.org/10.1159/000360010CrossRefPubMed

34.

Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83:308–315. https://doi.org/10.1038/ki.2012.345CrossRefPubMed

35.

Yasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, Tochikubo O (2002) Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis 39:1292–1299. https://doi.org/10.1053/ajkd.2002.33407CrossRefPubMed

36.

Gibiino G, Lopetuso LR, Scaldaferri F, Rizzatti G, Binda C, Gasbarrini A (2018) Exploring bacteroidetes: metabolic key points and immunological tricks of our gut commensals. Dig Liver Dis 50:635–639. https://doi.org/10.1016/j.dld.2018.03.016CrossRefPubMed

37.

Wu R, Ruan XL, Ruan DD, Zhang JH, Wang HL, Zeng QZ, Lu T, Gan YM, Luo JW, Wu JB (2021) Differences in gut microbiota structure in patients with stages 4–5 chronic kidney disease. Am J Transl Res 13:10056–10074PubMedPubMedCentral

38.

Zhu H, Cao C, Wu Z, Zhang H, Sun Z, Wang M, Xu H, Zhao Z, Wang Y, Pei G et al (2021) The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. https://doi.org/10.1016/j.cmet.2021.06.014CrossRefPubMedPubMedCentral

39.

Pavan M (2016) Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Min Urol Nefrol Ital J Urol Nephrol 68:222–226

40.

Huang H, Li K, Lee Y, Chen M (2021) Preventive effects of lactobacillus mixture against chronic kidney disease progression through enhancement of beneficial bacteria and downregulation of gut-derived uremic toxins. J Agric Food Chem 69:7353–7366. https://doi.org/10.1021/acs.jafc.1c01547CrossRefPubMed

41.

Sorbara MT, Pamer EG (2022) Microbiome-based therapeutics. Nat Rev Microbiol 20:365–380. https://doi.org/10.1038/s41579-021-00667-9CrossRefPubMed

42.

Sharma A, Das P, Buschmann M, Gilbert JA (2020) The future of microbiome-based therapeutics in clinical applications. Clin Pharmacol Ther 107:123–128. https://doi.org/10.1002/cpt.1677CrossRefPubMed

43.

Barba C, Soulage CO, Caggiano G, Glorieux G, Fouque D, Koppe L (2020) Effects of fecal microbiota transplantation on composition in mice with CKD. Toxins. https://doi.org/10.3390/toxins12120741CrossRefPubMedPubMedCentral

44.

Feng YL, Cao G, Chen DQ, Vaziri ND, Chen L, Zhang J, Wang M, Guo Y, Zhao YY (2019) Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cell Mol Life Sci 76:4961–4978. https://doi.org/10.1007/s00018-019-03155-9CrossRefPubMed

45.

Ozkok A, Elcioglu OC, Cukadar T, Bakan A, Sasak G, Atilgan KG, Alisir S, Kanbay M, Covic A, Odabas AR (2013) Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition-inflammation-atherosclerosis syndrome in patients with chronic kidney disease. Int Urol Nephrol 45:477–484. https://doi.org/10.1007/s11255-012-0237-6CrossRefPubMed

46.

Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R (2022) Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol 18:696–707. https://doi.org/10.1038/s41581-022-00616-6CrossRefPubMed

47.

Patel N, Yaqoob MM, Aksentijevic D (2022) Cardiac metabolic remodelling in chronic kidney disease. Nat Rev Nephrol 18:524–537. https://doi.org/10.1038/s41581-022-00576-xCrossRefPubMed

48.

Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM (2022) Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol 18:762–778. https://doi.org/10.1038/s41581-022-00621-9CrossRefPubMed

49.

Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The role of inflammation in CKD. Cells. https://doi.org/10.3390/cells12121581CrossRefPubMedPubMedCentral

50.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108. https://doi.org/10.1126/science.1208344CrossRefPubMedPubMedCentral

51.

Su G, Qin X, Yang C, Sabatino A, Kelly JT, Avesani CM, Carrero JJ (2022) Fiber intake and health in people with chronic kidney disease. Clin Kidney J 15:213–225. https://doi.org/10.1093/ckj/sfab169CrossRefPubMed

52.

Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B, Sanchez-Niño MD (2021) Phosphate, microbiota and CKD. Nutrients. https://doi.org/10.3390/nu13041273CrossRefPubMedPubMedCentral

53.

Naber T, Purohit S (2021) Chronic kidney disease: role of diet for a reduction in the severity of the disease. Nutrients. https://doi.org/10.3390/nu13093277CrossRefPubMedPubMedCentral

54.

Meléndez Oliva E, Villafañe JH, Alonso Pérez JL, Alonso Sal A, Molinero Carlier G, Quevedo García A, Turroni S, Martínez-Pozas O, Valcárcel Izquierdo N, Sánchez Romero EA (2022) Effect of exercise on inflammation in hemodialysis patients: a systematic review. J Personal Med. https://doi.org/10.3390/jpm12071188CrossRef

55.

Suzuki K (2019) Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules. https://doi.org/10.3390/biom9060223CrossRefPubMedPubMedCentral

56.

Wegierska AE, Charitos IA, Topi S, Potenza MA, Montagnani M, Santacroce L (2022) The connection between physical exercise and gut microbiota: implications for competitive sports athletes. Sports Med 52:2355–2369. https://doi.org/10.1007/s40279-022-01696-xCrossRefPubMedPubMedCentral

57.

König RS, Albrich WC, Kahlert CR, Bahr LS, Löber U, Vernazza P, Scheibenbogen C, Forslund SK (2021) The gut microbiome in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Front Immunol 12:628741. https://doi.org/10.3389/fimmu.2021.628741CrossRefPubMed

58.

Li F, Wang M, Wang J, Li R, Zhang Y (2019) Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease. Front Cell Infect Microbiol 9:206. https://doi.org/10.3389/fcimb.2019.00206CrossRefPubMedPubMedCentral

Title: Characterization of gut microbiota in patients with stage 3–4 chronic kidney disease: a retrospective cohort study
Authors: Xiali Yang
Shiying Cai
Jinsheng Gong
Jun Zhang
Minling Lian
Rufu Chen
Linghui Zhou
Peijin Bai
Bo Liu
Minting Zhuang
Honghong Tan
Juan Xu
Meizhen Li
Publication date: 12-12-2023
Publisher: Springer Netherlands
Keywords: Chronic Kidney Disease
Respiratory Microbiota
Biomarkers
Published in: International Urology and Nephrology / Issue 5/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-023-03893-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

Obesity and glomerular filtration rate

Paravesical aggressive angiomyxoma, a rare cause of pelvic tumor in men

Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones

How long do we need to reach sufficient expertise with the avatera® robotic system?

Enzyme-induced hypoxia leads to inflammation in urothelial cells in vitro

Ureteral stone volume and female gender predicts perioperative complications after complete ipsilateral upper urinary tract stone removal using flexible ureterorenoscopy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials